Eraso, A, Sanz, J, Molla, M, Reyes, V, Pedro, A, Arenas, M, Martinez, E, Ballester, R, Cambra, MJ, Garcia, V, Prades, JL, Borras, JM, Algara, M. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group. Clinical & Translational Oncology. 2022; 24(8)DOI:10.1007/s12094-022-02798-8. PMID:35190961. IF:3.400(Q3/6D).

Suarez, JF, Zamora, V, Garin, O, Gutierrez, C, Pont, A, Pardo, Y, Goni, A, Marino, A, Hervas, A, Herruzo, I, Cabrera, P, Sancho, G, de Leon, JP, Macias, V, Guedea, F, Vigues, F, Castells, M, Ferrer, M. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-16395-w. PMID:35869124. IF:4.600(Q2/4D).

Lara, PC, Rodriguez-Melcon, JI, Palacios-Eito, A, Lozano, A, Hervas-Moron, A, Villafranca, E, Gomez-Iturriaga, A, Sancho, G, Maldonado, X. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.891886. PMID:35912190. IF:4.700(Q2/4D).

Rodríguez F., Caruana P., De la Fuente N., Español P., Gámez M., Balart J., Llurba E., Rovira R., Ruiz R., Martín-Lorente C., Corchero J.L., Céspedes M.V.. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022; 12(6)DOI:10.3390/biom12060784. PMID:35740909. IF:5.500(Q1/3D).